1. Home
  2. PRCH vs ADCT Comparison

PRCH vs ADCT Comparison

Compare PRCH & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRCH

Porch Group Inc.

HOLD

Current Price

$6.78

Market Cap

753.7M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.62

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRCH
ADCT
Founded
2012
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.7M
484.4M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
PRCH
ADCT
Price
$6.78
$3.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
4
Target Price
$17.11
$7.75
AVG Volume (30 Days)
1.0M
750.6K
Earning Date
05-05-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
90.91
30.86
EPS
N/A
N/A
Revenue
$482,414,000.00
$81,357,000.00
Revenue This Year
$3.86
N/A
Revenue Next Year
$16.83
$68.29
P/E Ratio
N/A
N/A
Revenue Growth
10.18
14.85
52 Week Low
$4.65
$1.05
52 Week High
$19.44
$4.98

Technical Indicators

Market Signals
Indicator
PRCH
ADCT
Relative Strength Index (RSI) 37.94 39.10
Support Level $6.36 $3.25
Resistance Level $8.29 $3.87
Average True Range (ATR) 0.41 0.27
MACD -0.05 -0.06
Stochastic Oscillator 1.51 4.36

Price Performance

Historical Comparison
PRCH
ADCT

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: